Loading...
Market
Which major medical institution will Neuralink's Blindsight partner with by December 31, 2025?
2
Resolution / Starting Odds
Johns Hopkins University • 25%
Mayo Clinic • 25%
Cleveland Clinic • 25%
Other • 25%
Neuralink announcements, medical institution press releases
Story
Neuralink's Blindsight Receives FDA Breakthrough Device Designation on September 17, 2024
Sep 17, 2024, 07:12 PM
Neuralink, the brain-chip startup founded by Elon Musk, has received the U.S. Food and Drug Administration's (FDA) Breakthrough Device Designation for its brain implant chip named Blindsight on September 17, 2024. This designation is given when preliminary clinical evidence suggests that the device may offer substantial improvement over existing treatments. Blindsight aims to restore vision in individuals who were born blind or have lost their eyesight, including those without optic nerves, provided their visual cortex is intact. The device has already demonstrated success in monkeys and allows patients to control a mouse using only their thoughts. Blindsight is Neuralink's next product after Telepathy.
View original story
Similar markets
Google • 25%
Apple • 25%
Microsoft • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant improvement in vision • 25%
Moderate improvement in vision • 25%
No noticeable improvement • 25%
Negative side effects • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
0-10 • 25%
11-50 • 25%
51-100 • 25%
More than 100 • 25%
Yes • 50%
No • 50%
Tesla • 25%
Google • 25%
Microsoft • 25%
Other • 25%
Infrared vision capability • 25%
Ultraviolet vision capability • 25%
Both infrared and ultraviolet vision capabilities • 25%
Neither capability • 25%